Shasqi is a biotech company whose mission is to revolutionize cancer treatment with click chemistry, a 2022 Nobel Prize winning technology. Our unique CAPAC® (Click Activated Protodrugs Against Cancer) platform uses click chemistry to target high doses of cancer drugs directly to the site of the tumor while minimizing toxicity to healthy cells, potentially improving the therapeutic index. Shasqi has developed an expansive and diverse library of antibody-mediated tumor-targeting agents and cancer therapeutic payloads. These are decoupled from each other and reunited at the site of the tumor via a click chemistry reaction. We are the first company to use click chemistry in humans. For more information, visit us at www.shasqi.com